AN2025

21 2023-10

ESMO Poster
Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN

30 2023-05

ASCO Poster
Combination of Immune and Genetic Biomarkers of Improved Efficacy to Buparlisib and Paclitaxel in Patients with SCCHN: BERIL-1 Sub-analysis

10 2023-04

Radiotherapy & Oncology
AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer

05 2022-12

SABCS Poster
A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/static breast cancer (REO 026-1)

15 2022-02

Frontiers in Immunology
Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity

13 2021-04

AACR Poster
AN3025: an immune-stimulatory anti-human TNFR2 antibody with strong anti-tumor activity

16 2020-06

Journal for ImmunoTherapy of Cancer
First-in- human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers

26 2019-09

ESMO Poster
A Phase 1b Study of E7046 (AN0025) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Rectal Cancer

17 2019-07

JSMO Poster
A novel CSF1R/c-kit dual antagonist eliminates tumor associated macrophage without elevating intratumoral MDSC level

14 2019-03

ICHNO Poster
Buparlisib(AN2025), a potential treatment option for anti PD 1 non responding tumors

27 2018-02

Clinical Cancer Research
Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1

12 2017-10

Breast Cancer Res Treat
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with static breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

24 2017-01

Lancet Oncol
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or static squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial